

Dimos Baltas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9202205/publications.pdf>

Version: 2024-02-01

44
papers

761
citations

567281
15
h-index

552781
26
g-index

44
all docs

44
docs citations

44
times ranked

1098
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. <i>Theranostics</i> , 2019, 9, 2595-2605.	10.0	105
2	One-Shot Learning for Deformable Medical Image Registration and Periodic Motion Tracking. <i>IEEE Transactions on Medical Imaging</i> , 2020, 39, 2506-2517.	8.9	66
3	Esophagus segmentation in CT via 3D fully convolutional neural network and random walk. <i>Medical Physics</i> , 2017, 44, 6341-6352.	3.0	64
4	Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. <i>Radiation Oncology</i> , 2018, 13, 81.	2.7	53
5	Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. <i>Radiotherapy and Oncology</i> , 2017, 123, 472-477.	0.6	50
6	High dose rate brachytherapy as monotherapy for localised prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 270-277.	0.6	34
7	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. <i>Journal of Nuclear Medicine</i> , 2021, 62, 823-828.	5.0	32
8	The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2020, 150, 128-135.	0.6	28
9	The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. <i>Radiation Oncology</i> , 2018, 13, 65.	2.7	26
10	FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?. <i>Radiation Oncology</i> , 2021, 16, 46.	2.7	24
11	Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2016, 3, 241-248.	0.9	22
12	FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy. <i>Cancers</i> , 2021, 13, 814.	3.7	21
13	18F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy. <i>Cancers</i> , 2021, 13, 3449.	3.7	19
14	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. <i>Cancers</i> , 2021, 13, 5795.	3.7	19
15	Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. <i>Theranostics</i> , 2020, 10, 9395-9406.	10.0	16
16	GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy. <i>Radiotherapy and Oncology</i> , 2020, 148, 51-56.	0.6	16
17	Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 301-307.	0.6	14
18	Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial. <i>Journal of Nuclear Medicine</i> , 2021, 62, 471-478.	5.0	14

#	ARTICLE	IF	CITATIONS
19	Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference. <i>Frontiers in Oncology</i> , 2021, 11, 652678.	2.8	12
20	PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 1025-1035.	0.8	12
21	Monte Carlo and experimental high dose rate ¹⁹² Ir brachytherapy dosimetry with microDiamond detectors. <i>Zeitschrift Fur Medizinische Physik</i> , 2019, 29, 272-281.	1.5	11
22	Radiobiological evaluation of prostate cancer IMRT and conformal-RT plans using different treatment protocols. <i>Physica Medica</i> , 2017, 40, 33-41.	0.7	10
23	CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 1171-1179.	2.0	10
24	Experimental phantom evaluation to identify robust positron emission tomography (PET) radiomic features. <i>EJNMMI Physics</i> , 2021, 8, 46.	2.7	10
25	Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation – Post-hoc analysis from a prospective imaging trial. <i>Radiotherapy and Oncology</i> , 2021, 159, 75-81.	0.6	8
26	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. <i>Future Oncology</i> , 2018, 14, 751-769.	2.4	7
27	Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition. <i>Radiation Oncology</i> , 2020, 15, 242.	2.7	7
28	Optimization of hippocampus sparing during whole brain radiation therapy with simultaneous integrated boost – tutorial and efficacy of complete directional hippocampal blocking. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 537-546.	2.0	7
29	Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. <i>Brachytherapy</i> , 2019, 18, 829-834.	0.5	6
30	Evolution of the hypoxic compartment on sequential oxygen partial pressure maps during radiochemotherapy in advanced head and neck cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 100-105.	2.9	6
31	Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 62-67.	0.6	4
32	Investigating the role of constrained CVT and CVT in HIPO inverse planning for HDR brachytherapy of prostate cancer. <i>Medical Physics</i> , 2019, 46, 2955-2968.	3.0	4
33	Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation – results from a prospective pilot trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1650-1660.	6.4	4
34	The Bebig Valencia-type skin applicators: Dosimetric study and implementation of a dosimetric hybrid technique. <i>Brachytherapy</i> , 2017, 16, 1044-1056.	0.5	3
35	Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 215-220.	0.9	3
36	Suitability of the microDiamond detector for experimental determination of the anisotropy function of High Dose Rate ¹⁹² Ir brachytherapy sources. <i>Medical Physics</i> , 2020, 47, 5838-5851.	3.0	3

#	ARTICLE	IF	CITATIONS
37	High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. <i>Frontiers in Oncology</i> , 2021, 11, 770959.	2.8	3
38	The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 120-127.	1.7	3
39	Biological imaging for individualized therapy in radiation oncology: part I physical and technical aspects. <i>Future Oncology</i> , 2018, 14, 737-749.	2.4	2
40	Source strength determination in iridium-192 and cobalt-60 brachytherapy: A European survey on the level of agreement between clinical measurements and manufacturer certificates. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 19, 108-111.	2.9	2
41	Inverse planning and inverse implanting for breast interstitial brachytherapy. Introducing a new anatomy specific breast interstitial template (ASBIT). <i>Radiotherapy and Oncology</i> , 2018, 128, 421-427.	0.6	1
42	Measuring breathing induced oesophageal motion and its dosimetric impact. <i>Physica Medica</i> , 2021, 88, 9-19.	0.7	0
43	Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1072, 195-200.	1.6	0
44	Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 260-260.	1.6	0